Contributions of stochastic events to biological evolution and cancer
Journal Title: Journal of Cancer Research & Therapy - Year 2015, Vol 3, Issue 9
Abstract
Stochastic genetic and epigenetic events have been fundamental in contributing to the development of manifold life-forms, past and present. The development of malignant cell clones and the role of stochasticity as a driving force in cancer cell evolution complements, in a perverse way evidence for the role of chance in normal cellular development and evolution. Stochastic events at multiple levels of cellular control and implementation represent a primary driving force and an ultimate filter through which evolutionary innovation occurs. Stochasticity provides the opportunity for a random assortment of disparate genetic and epigenetic events, in some instances resulting in altered metabolic and developmental capabilities of sufficient stability and uniqueness to contribute to deterministic sequelae that promote the viability and procreation of cells under stress. Cellular evolution has so far resulted in a “survival of a (sic) fittest”, often dependent mechanistically on and determined by stochastic events. The implications of this are mirrored in the evolution of malignant change, to some extent as a variant of “reverse engineering” of dedifferentiation. Efforts to reduce the incidence of malignant change will have to take in to account its random nature and further the understanding of this feature.
Authors and Affiliations
Anderson KM, Rubenstein M, Guinan P, Patel MK
Keywords
Related Articles
- EP ID EP546041
- DOI 10.14312/2052-4994.2015-15
- Views 61
- Downloads 0
Apocrine carcinoma of the scalp – A case report and highlights for diagnosis
Apocrine sweat gland carcinoma is a rare cutaneous adnexal neoplasm that may occur in the scalp, eyelid, and ear canal. More often, it presents as an asymptomatic, slow-growing, solid or cystic mass with variable color....
Trastuzumab therapy in metastatic bladder carcinoma: The proof of concept
About 10% of metastatic urothelial carcinoma overexpress oncogenic HER2/neu receptor. Recent preliminary data suggest that patients with this particular molecular subset could benefit from trastuzumab therapy, which spec...
Adjuvant concurrent docetaxel, epirubicin and cyclophosphamide chemotherapy in breast cancer: The TEC regimen. A retrospective analysis
Background: The use of taxanes and anthracyclines in the adjuvant treatment of primary breast cancer is well established, with benefit in both disease free survival (DFS) and overall survival (OS). Several studies demons...
The prevention and treatment of peritoneal carcinomatosis from gastric cancer: A 2013 update
Gastric cancer is the fourth most common cancer and the second leading cause of cancer death in the world. Penetration of the gastric serosa and lymphatic spread are the two most important factors affecting prognosis in...
A single center series highlights on incidence and management of gastric neuroendocrine tumours with literature review
Neuroendocrine tumours of the digestive system (GEP-NET) are relatively rare. Nevertheless, their diagnoses is rising as seen from studies in the US and elsewhere. Gastric neuroendocrine tumours (Gastric NETs) vary throu...